Literature DB >> 10348313

A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.

S D Taylor-Robinson1, N Turjanski, S Bhattacharya, J P Seery, J Sargentoni, D J Brooks, D J Bryant, I J Cox.   

Abstract

Animal studies have suggested an increased striatal glutamate activity in Parkinson's disease models, although this has not been substantiated in magnetic resonance spectroscopy studies in patients. Our initial aim was to assess glutamate and glutamine levels in the striatum of patients with idiopathic Parkinson's disease, using multivoxel proton magnetic resonance spectroscopy techniques. Since data were collected from other areas of the brain without a priori selection, information on the cortex was also obtained. Twelve healthy volunteers, seven dyskinetic and five non-dyskinetic patients were studied. Peak area ratios of choline-containing compounds (Cho), glutamine and glutamate (Glx) and N-acetyl moieties including N-acetylaspartate (NAx), relative to creatine (Cr) were calculated. Spectra were analysed from the corpus striatum, the occipital cortex and the temporo-parietal cortex. The median Glx/Cr ratio was unaltered in the striatal spectra of Parkinson's disease patients compared to healthy controls. However, the more severely affected patients had significantly reduced NAx/Cr ratios in spectra localised to the temporo-parietal cortex, compared to healthy controls. Furthermore, the entire patient population had significantly reduced Cho/Cr ratios in spectra from the temporo-parietal cortex, compared to the reference population. We found no evidence of increased striatal glutamate in either dyskinetic or non-dyskinetic Parkinson's disease. However, the low NAx/Cr and Cho/Cr ratios in the temporo-parietal cortex may indicate the presence of subclinical cortical dysfunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348313     DOI: 10.1023/a:1020609530444

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  37 in total

Review 1.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

2.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.

Authors:  L Verhagen Metman; P Del Dotto; P van den Munckhof; J Fang; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

3.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines.

Authors:  T F Freund; J F Powell; A D Smith
Journal:  Neuroscience       Date:  1984-12       Impact factor: 3.590

4.  A knowledge-based approach to deconvolve the water component in in vivo proton MR spectroscopy.

Authors:  N Saeed
Journal:  J Comput Assist Tomogr       Date:  1995 Sep-Oct       Impact factor: 1.826

5.  Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

Authors:  D Bravi; M M Mouradian; J W Roberts; T L Davis; Y H Sohn; T N Chase
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

6.  Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.

Authors:  F Federico; I L Simone; V Lucivero; M De Mari; P Giannini; G Iliceto; D M Mezzapesa; P Lamberti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

7.  MR imaging and spectroscopy of the basal ganglia in chronic liver disease: correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra.

Authors:  S D Taylor-Robinson; J Sargentoni; A Oatridge; D J Bryant; J V Hajnal; C D Marcus; J P Seery; H J Hodgson; N M deSouza
Journal:  Metab Brain Dis       Date:  1996-09       Impact factor: 3.584

8.  Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism.

Authors:  J C Zijlmans; A de Koster; M A van 't Hof; H O Thijssen; M W Horstink; A Heerschap
Journal:  Acta Neurol Scand       Date:  1994-12       Impact factor: 3.209

9.  Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy.

Authors:  S D Taylor-Robinson; J Sargentoni; C D Marcus; M Y Morgan; D J Bryant
Journal:  Metab Brain Dis       Date:  1994-12       Impact factor: 3.584

10.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.

Authors:  C A Davie; G J Barker; S Webb; P S Tofts; A J Thompson; A E Harding; W I McDonald; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

View more
  10 in total

Review 1.  Metabolic disturbances in diseases with neurological involvement.

Authors:  João M N Duarte; Patrícia F Schuck; Gary L Wenk; Gustavo C Ferreira
Journal:  Aging Dis       Date:  2013-11-30       Impact factor: 6.745

Review 2.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

3.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

Review 4.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

5.  Detection and application of neurochemical profile by multiple regional 1H-MRS in Parkinson's disease.

Authors:  Jitian Guan; Yu Rong; Ye Wen; Huanze Wu; Hong Qin; Qingying Zhang; Wei Chen
Journal:  Brain Behav       Date:  2017-08-13       Impact factor: 2.708

6.  Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson's Disease.

Authors:  Ekaterina Zhurakovskaya; Juuso Leikas; Tiina Pirttimäki; Francesc Casas Mon; Mikko Gynther; Rubin Aliev; Tomi Rantamäki; Heikki Tanila; Markus M Forsberg; Olli Gröhn; Jaakko Paasonen; Aaro J Jalkanen
Journal:  eNeuro       Date:  2019-02-26

Review 7.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

8.  Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study.

Authors:  Lilla Bonanno; Rosella Ciurleo; Silvia Marino; Claudio Ruvolo; Rosa Morabito; Alessia Bramanti; Francesco Corallo
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

9.  Does Prefrontal Glutamate Index Cognitive Changes in Parkinson's Disease?

Authors:  Isabelle Buard; Natalie Lopez-Esquibel; Finnuella J Carey; Mark S Brown; Luis D Medina; Eugene Kronberg; Christine S Martin; Sarah Rogers; Samantha K Holden; Michael R Greher; Benzi M Kluger
Journal:  Front Hum Neurosci       Date:  2022-04-12       Impact factor: 3.473

Review 10.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.